Observation Of Conbercept Treatment On Exudative Age-related Macular Degeneration

Objective To observe the clinical efficiency and safety of intravitreal(conbercept),a novel VEGF decoy receptor fusion protein in exudative age related macular degeneration(e AMD).Methods Twenty-five eyes which were diagnosed with e AMD by ophthalmologist though the results of fundus fluorescein angiography(FFA)and optical coherence tomography(OCT)were enrolled in the study.All the eyes were injected conbercept with 0.05 ml(10 mg/ml)each time,following a ‘3+PRN' schedule intravenously.This was a self-control study.The best corrected visual acuity(BCVA)was tested according with the criterion of the early treatment of diabetic retinopathy study(ETDRS).Optical coherence tomography(OCT)was used to examine the central macular thickness(CMT),Amsler grid was used to examine the degree of visual distortion,FFA was used to examine the leakage of choroidal neovascularization.The comparative analysis was used to observe the changes of BCVA,CMT before and after treatment.Simultaneously,the occurrences of ocular and systemic adverse reactions were observed during follow-up duration.Results The initial average letters of BCVA were(41.80±20.86).The initial average(CMT)was 493.52±87.81 ?m.The first three months of treatment plus the last follow-up time,the average follow-up time was 4.25±0.79 months.After each treatment,the average letters of BCVA were(49.84±20.70)?(53.84±21.22)?(57.04±21.43)?(56.40±21.41).Compared to the initial average letters of BCVA(41.80±20.86),each month the average letters of BCVA improved(8.04±9.42)?(12.04±9.36)?(15.24±9.84)?(14.60±9.92)letters.There was a conspicuous difference between each follow-up time and baseline(t=4.27?6.43?7.75?7.36,P<0.01).Compare the average letter of BCVA each follow-up and last reexamination,there was a conspicuous difference between the first three pairs(t=4.27?3.00?3.80? P<0.01).The last pairs,3months and latest reexamination,there wasn't a conspicuous difference;After each treatment the average CMT were(430.6±74.66)?(391.36±68.89)?(359.52±71.54)?(365.64±81.85)?m.Compared to the initial average CMT decreased(62.92±26.27)?(102.16±48.69)?(134±66.87)?(127±73.78)?m.There was a conspicuous difference between each follow-up time and baseline(t=11.97,10.49,10.02,8.67 P<0.05).Compare the average data of CMT each follow-up and last reexamination,there was a conspicuous difference between the first three pairs(t=11.97?5.51?5.10?P<0.01).The last pairs,3months and latest reexamination,there wasn't a conspicuous difference.No adverse events such as secondary retinal detachment,vitreous hemorrhage,intraocular pressure continues to rise,uveitis,endophthalmitis and treatment-related serious ocular complications were found during the follow-up duration,also no systemic adverse reactions.Conclusion Intravitreal conbercept is a safe and effective approach for e AMD,and it also can improve visual acuity,reduce macular edema,and inhibit choroidal neovascularization,its long-term efficacy and safety remains to be seen in the future.